Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

NCT04088071 · View on ClinicalTrials.gov ↗

Study Summary

The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.

Interventions

  • DEVICE Catheter ablation

Study Locations (20)

Florida

  • Ascension St. Vincent's — Jacksonville
  • HCA Florida Mercy Hospital — Miami
  • Naples Community Hospital — Naples
  • Ascension Sacred Heart — Pensacola
  • Sarasota Memorial Hospital — Sarasota
  • Baycare Health System — Winter Haven

California

  • Keck School of Medicine — Los Angeles
  • Santa Barbara Cottage Hospital — Santa Barbara
  • Community Memorial Hospital — Ventura
  • University HealthCare Alliance — Walnut Creek

Alabama

  • University of Alabama at Birmingham — Birmingham
  • Grandview Medical Center — Birmingham
  • Cardiology Associates of Mobile — Mobile

Colorado

  • The Medical Center of Aurora — Aurora
  • Colorado Heart and Vascular — Golden
  • South Denver Cardiology — Littleton

Georgia

  • Piedmont Healthcare — Atlanta
  • Memorial Health University Medical Center — Savannah

Arizona

  • Valley Heart Rhythm Specialists — Chandler

Arkansas

  • Arrhythmia Research Group — Jonesboro

Trial Details

FieldValue
Enrollment Target 15,000 participants
Start Date 2018-01-01
Est. Completion 2027-12-31

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04088071

The ClinicalTrials.gov registry entry for NCT04088071 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heart Rhythm Clinical and Research Solutions, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which Catheter ablation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04088071 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04088071 about?

NCT04088071 is a clinical study titled "Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation". The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long...

What is the current status of trial NCT04088071?

This trial is currently recruiting. The enrollment target is 15,000 participants. The study started on 2018-01-01. Estimated completion is 2027-12-31.

What conditions does trial NCT04088071 study?

This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04088071?

The interventions under investigation include: Catheter ablation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04088071?

This trial is sponsored by Heart Rhythm Clinical and Research Solutions, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04088071 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial